Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

The effectiveness of financial incentives for COVID-19 vaccination: A systematic review
Gabriela Kattan Khazanov, Rebecca Stewart, Matteo F. Pieri, et al.
Preventive Medicine (2023) Vol. 172, pp. 107538-107538
Open Access | Times Cited: 19
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 15
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
Masaud Shah, Sung Ung Moon, Ji‐Yon Shin, et al.
Advanced Science (2025)
Open Access
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
Qiao Wang, Lujia Sun, Shibo Jiang
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 8
The Immunogenicity of CpG, MF59-Like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice
Kangwei Xu, Jing Li, Lu Xu, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 60-60
Open Access | Times Cited: 2
Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters
Yolandy Lemmer, Rosamund Chapman, Célia Abolnik, et al.
Vaccine (2024) Vol. 42, Iss. 4, pp. 738-744
Open Access | Times Cited: 2
Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study
Rong Tang, Ying Zeng, Yu Zhou, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 498-509
Open Access | Times Cited: 2
Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice
Jian‐Piao Cai, Cuiting Luo, Kun Wang, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 687-687
Open Access | Times Cited: 5
Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters
Levi Tamming, Diana Duque, Jegarubee Bavananthasivam, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 3, pp. 101325-101325
Open Access | Times Cited: 1
Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing
Theodora U. J. Bruun, Jonathan Do, Payton A. Weidenbacher, et al.
ACS Central Science (2024) Vol. 10, Iss. 10, pp. 1871-1884
Open Access | Times Cited: 1
Update on Innate Immunity in Acute Kidney Injury—Lessons Taken from COVID-19
Kinga Musiał
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12514-12514
Open Access | Times Cited: 4
Epitope delimitation: A new method for defining epitopes of human IgG‐reactive antigenic peptides based on rabbit‐recognized epitope motifs
Haiping Tang, Ya‐Ping He, Jian Wang, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Closed Access
A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model
Yi Zhang, Jialu Zhang, Dongmei Li, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 484-484
Open Access
Engineering a SARS-CoV-2 vaccine targeting the RBD cryptic-face via immunofocusing
Theodora U. J. Bruun, Jonathan Do, Payton A. Weidenbacher, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice
William Becker, Khadija Rebbani, Zhijian Duan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
SARS-COV-2 ІНФЕКЦІЯ У ДІТЕЙ ЛЬВІВЩИНИ
Halyna Lytvyn, Leonid Dubey, М.В. Стасів, et al.
Proceedings of the Shevchenko Scientific Society Medical Sciences (2024) Vol. 76, Iss. 2
Open Access
Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
Zezhong Liu, Lu Lu, Shibo Jiang
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 1
The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC–MS
Kangwei Xu, Huang Sun, Kaiqin Wang, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 1002-1002
Open Access | Times Cited: 1
SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: The COmmunity Cohort Study
Vivienne C. Bachelet, Ignacio Silva-Ayarza, María S Navarrete
Medwave (2023) Vol. 23, Iss. 11, pp. e2787-e2787
Open Access | Times Cited: 1
Prediction of Potential Repurposed Drugs against SARS-CoV-2 based on Text Mining and Molecular Docking Analysis
Jie Zhou, Yi-Qing Xu
(2023) Vol. 4, pp. 1463-1469
Closed Access
Page 1

Scroll to top